Trial Watch-Oncolytic viruses and cancer therapy.
Oncoimmunology
; 5(2): e1117740, 2016 Feb.
Article
em En
| MEDLINE
| ID: mdl-27057469
ABSTRACT
Oncolytic virotherapy relies on the administration of non-pathogenic viral strains that selectively infect and kill malignant cells while favoring the elicitation of a therapeutically relevant tumor-targeting immune response. During the past few years, great efforts have been dedicated to the development of oncolytic viruses with improved specificity and potency. Such an intense wave of investigation has culminated this year in the regulatory approval by the US Food and Drug Administration (FDA) of a genetically engineered oncolytic viral strain for use in melanoma patients. Here, we summarize recent preclinical and clinical advances in oncolytic virotherapy.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
Oncoimmunology
Ano de publicação:
2016
Tipo de documento:
Article